Abstrakt

Serum uromodulin (sURO) was recently found as a sensitive tubular marker in early chronic kidney disease stages. Thus far, mainly early uromodulin urinary excretion was tested in kidney recipients. The aim of our study was to conduct a long-lastinlong-term assessment of sURO in kidney graft function monitoring. Forty-one stable kidney recipients (aged 47 (13.7)) were studied around the 3^rd month (3m) and the 2^nd year (2y) after kidney transplantation. Sera were tested for sURO, creatinine and tacrolimus levels. Kidney biopsy was scored according to revised Banff 97 classification. sURO level (mean 66.06ng/ml at 3m; 77.81 at 2y) increased borderline significantly (P = 0.051) in time and significantly correlated with eGFR (3m RS = 0.46; 2y RS = 0.58), creatinine levels (RS respectively –0.55 and –0.56) and donor age (3m Rs = –0.33; 2y RS = –0.41). We observed borderline correlations between sURO and Banff biopsy scoring: 3m-sURO with arteriolar hyalinosis-ah (RS = –0.3, P = 0.06) and 2y-sURO with peritubular capillaritis-ptc (RS = 0.45, P = 0.07). Correlations of sURO with 3m tacrolimus levels (Rs = 0.3, P = 0.08) were borderline, however patients with CNI toxicity lesions in biopsy had sURO significantly lower (mean 3m-sURO 52.7 vs 83.1 ng/ml; 2y-sURO 61.9 vs 98.1 ng/ml). sURO can reflect kidney graft quality and function. sURO correlated with ptc, which is considered to be an early marker of a chronic antibody-mediated graft injury. Tacrolimus doesn’t influence sURO levels directly, but sURO is lower in patients with toxic kidney injury in biopsy.

Przypisy

• 1. Bostom A., Steubl D., Garimella P.S., Franceschini N., Roberts M.B.,Pasch A., Ix J.H., Tuttle K.R., Ivanova A., Shireman T., Kim S.J., Gohh R.,Weiner D.E., Levey A.S., Hsu C.Y., et al.: Serum uromodulin: a biomarkerof long-term kidney allograft failure. Am. J. Nephrol., 2018; 47: 275–282 2 Bostom A.G., Steubl D., Friedman A.N.: Hypothesis: potential utilityof serum and urine uromodulin measurement in kidney transplantrecipients? Transplant. Direct, 2017; 3: e219
  Google Scholar
• 2. and familial juvenile hyperuricaemic nephropathy. J. Med. Genet.,2002; 39: 882–892
  Google Scholar
• 3. Bröcker V., Schubert V., Scheffner I., Schwarz A., Hiss M., BeckerJ.U., Scherer R., Haller H., Kreipe H.H., Mengel M., Gwinner W.:Arteriolar lesions in renal transplant biopsies: prevalence, progression,and clinical significance. Am. J. Pathol., 2012; 180: 1852–1862
  Google Scholar
• 4. Dahan K., Devuyst O., Smaers M., Vertommen D., Loute G., PouxJ.M., Viron B., Jacquot C., Gagnadoux M.F., Chauveau D., BüchlerM., Cochat P., Cosyns J.P., Mougenot B., Rider M.H., et al.: A clusterof mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J.Am. Soc. Nephrol., 2003; 14: 2883–2893
  Google Scholar
• 5. Dawnay A.B., Cattell W.R.: Serum Tamm-Horsfall glycoproteinlevels in health and in renal disease. Clin. Nephrol., 1981; 15: 5–8
  Google Scholar
• 6. de Matos A.C., Câmara N.O., REQUIãO-Moura L.R., Tonato E.J., FiliponiT.C., Souza-DURãO M. Jr, Malheiros D.M., Fregonesi M., BorrelliM., Pacheco-Silva A.: Presence of arteriolar hyalinosis in post-reperfusionbiopsies represents an additional risk to ischaemic injury inrenal transplant. Nephrology 2016; 21: 923–929
  Google Scholar
• 7. Devuyst O., Dahan K., Pirson Y.: Tamm-Horsfall protein or uromodulin:new ideas about an old molecule. Nephrol. Dial. Transplant.,2005; 20: 1290–1294
  Google Scholar
• 8. Fedak D., Kuźniewski M., Fugiel A., Wieczorek-Surdacka E., Przepiórkowska-Hoyer B., Jasik P., Miarka P., Dumnicka P., Kapusta M.,Solnica B., Sułowicz W.: Serum uromodulin concentrations correlatewith glomerular filtration rate in patients with chronic kidneydisease. Pol. Arch. Med. Wewn., 2016; 126: 995–1004
  Google Scholar
• 9. Gibson I.W., Gwinner W., Bröcker V., Sis B., Riopel J., Roberts I.S.,Scheffner I., Jhangri G.S., Mengel M.: Peritubular capillaritis in renalallografts: prevalence, scoring system, reproducibility and clinicopathologicalcorrelates. Am. J. Transplant., 2008; 8: 819–825
  Google Scholar
• 10. Hart T.C., Gorry M.C., Hart P.S., Woodard A.S., Shihabi Z., SandhuJ., Shirts B., Xu L., Zhu H., Barmada M.M., Bleyer A.J.: Mutations ofthe UMOD gene are responsible for medullary cystic kidney disease
  Google Scholar
• 11. Kaden J., Groth J., May G., Liedvogel B.: Urinary Tamm-Horsfallprotein as a marker of renal transplant function. Urol. Res., 1994;22: 131–136
  Google Scholar
• 12. Kobayashi K., Fukuoka S.: Conditions for solubilization of Tamm-Horsfall protein/uromodulin in human urine and establishment of asensitive and accurate enzyme-linked immunosorbent assay (ELISA)method. Arch. Biochem. Biophys., 2001; 388: 113–120
  Google Scholar
• 13. Köttgen A., Glazer N.L., Dehghan A., Hwang S.J., Katz R., Li M.,Yang Q., Gudnason V., Launer L.J., Harris T.B., Smith A.V., Arking D.E.,Astor B.C., Boerwinkle E., Ehret G.B., et al.: Multiple loci associatedwith indices of renal function and chronic kidney disease. Nat Genet.,2009; 41: 712–717
  Google Scholar
• 14. Kozakowski N., Herkner H., Böhmig G.A., Regele H., KornauthC., Bond G., Kikić Ž.: The diffuse extent of peritubular capillaritis inrenal allograft rejection is an independent risk factor for graft loss.Kidney Int., 2015; 88: 332–340
  Google Scholar
• 15. Lerut E., Naesens M., Kuypers D.R., Vanrenterghem Y., Van DammeB.: Subclinical peritubular capillaritis at 3 months is associatedwith chronic rejection at 1 year. Transplantation, 2007; 83: 1416–1422
  Google Scholar
• 16. Ling X.B., Sigdel T.K., Lau K., Ying L., Lau I., Schilling J., SarwalM.M.: Integrative urinary peptidomics in renal transplantationidentifies biomarkers for acute rejection. J. Am. Soc. Nephrol.,2010; 21: 646–653
  Google Scholar
• 17. McLaughlin P.J., Aikawa A., Davies H.M., Ward R.G., Bakran A.,Sells R.A., Johnson P.M.: Uromodulin levels are decreased in urineduring acute tubular necrosis but not during immune rejection afterrenal transplantation. Clin. Sci., 1993; 84: 243–246
  Google Scholar
• 18. Mo L., Huang H., Zhu X., Shapiro E., Hasty D.L., Wu X.R.: Tamm-Horsfall protein is a critical renal defense factor protecting againstcalcium oxalate crystal formation. Kidney Int., 2004; 66: 1159–1166
  Google Scholar
• 19. Padmanabhan S., Melander O., Johnson T., Di Blasio A.M., LeeW.K., Gentilini D., Hastie C.E., Menni C., Monti M.C., Delles C., Laing S., Corso B., Navis G., Kwakernaak A.J., van der Harst P., et al.: Genome-wide association study of blood pressure extremes identifiesvariant near UMOD associated with hypertension. PLoS Genet.,2010; 6: e1001177
  Google Scholar
• 20. Prajczer S., Heidenreich U., Pfaller W., Kotanko P., Lhotta K.,Jennings P.: Evidence for a role of uromodulin in chronic kidneydisease progression. Nephrol. Dial. Transplant., 2010; 25: 1896–1903
  Google Scholar
• 21. Racusen L.C., Bagnasco S.M.: Peritubular capillaritis in the renalallograft takes center stage. Kidney Int., 2015; 88: 218–220
  Google Scholar
• 22. Reznichenko A., Böger C.A., Snieder H., van den Born J., de BorstM.H., Damman J., van Dijk M.C., van Goor H., Hepkema B.G., HillebrandsJ.L., Leuvenink H.G., Niesing J., Bakker S.J., Seelen M., NavisG.; REGaTTA (REnal GeneTics TrAnsplantation) Groningen group.:UMOD as a susceptibilitygene for end-stage renal disease. BMCMed. Genet, 2012; 13: 78
  Google Scholar
• 23. Reznichenko A., van Dijk M.C., van der Heide J.H., Bakker S.J.,Seelen M., Navis G.: Uromodulin in renal transplant recipients: elevatedurinary levels and bimodal association with graft failure. Am.J. Nephrol., 2011; 34: 445–451
  Google Scholar
• 24. Risch L., Lhotta K., Meier D., Medina-Escobar P., Nydegger U.E.,Risch M.: The serum uromodulin level is associated with kidneyfunction. Clin. Chem. Lab. Med., 2014; 52: 1755–1761
  Google Scholar
• 25. Schwartz R.H., Van Ess J.D., May A.G., Schenk E.A., FreemanR.B.: Tamm-Horsfall glycoproteinuria and renal allograft rejection.Transplantation, 1973; 16: 83–87
  Google Scholar
• 26. Serafini-Cessi F., Malagolini N., Cavallone D.: Tamm-Horsfallglycoprotein:biology and clinical relevance. Am. J. Kidney Dis., 2003;42: 658–676
  Google Scholar
• 27. Solez K., Colvin R.B., Racusen L.C., Haas M., Sis B., Mengel M.,Halloran P.F., Baldwin W., Banfi G., Collins A.B., Cosio F., David D.S.,Drachenberg C., Einecke G., Fogo A.B., et al.: Banff 07 classificationof renal allograft pathology: updates and future directions. Am. J.Transplant., 2008; 8: 753–760
  Google Scholar
• 28. Steubl D., Block M., Herbst V., Nockher W.A., Schlumberger W.,Satanovskij R., Angermann S., Hasenau A.L., Stecher L., HeemannU., Renders L., Scherberich J.: Plasma uromodulin correlates withkidney function and identifies early stages in chronic kidney diseasepatients. Medicine 2016; 95: e3011
  Google Scholar
• 29. Steubl D., Block M., Herbst V., Schlumberger W., Nockher A.,Angermann S., Schmaderer C., Heemann U., Renders L., ScherberichJ.: Serum uromodulin predicts graft failure in renal transplantrecipients. Biomarkers, 2017; 22: 171–177
  Google Scholar
• 30. Trudu M., Janas S., Lanzani C., Debaix H., Schaeffer C., IkehataM., Citterio L., Demaretz S., Trevisani F., Ristagno G., GlaudemansB., Laghmani K., Dell’Antonio G.; SKIPOGH team, Loffing J., RastaldiM.P., et al.: Common noncoding UMOD gene variants induce salt-sensitivehypertension and kidney damage by increasing uromodulinexpression. Nat. Med., 2013; 19: 1655–1660
  Google Scholar
• 31. Uslu A., Hür E., Şen Ç., Şen S., Akgün A., Taşlı F.A., Nart A., YilmazM., Töz H.: To what extent estimated or measured GFR couldpredict subclinical graft fibrosis: a comparative prospective studywith protocol biopsies. Transplant. Int., 2015; 28: 575–581
  Google Scholar
• 32. Vyletal P., Bleyer A.J., Kmoch S.: Uromodulin biology and pathophysiology-an update. Kidney Blood Press. Res., 2010; 33: 456–475
  Google Scholar

Pełna treść artykułu